Cardinal Health (CAH)
(Delayed Data from NYSE)
$112.55 USD
+0.57 (0.51%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.56 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.55 USD
+0.57 (0.51%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.56 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
3 Companies Reporting Remarkable Results: WMT, LLY, CAH
by Derek Lewis
All three companies posted robust results and upped their outlooks, a bullish pairing. Is it time to buy?
Company News for Aug 15, 2024
by Zacks Equity Research
Companies in The News Are: CAH,UBS,EAT,ESLT
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Here's What Key Metrics Tell Us About Cardinal (CAH) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 6.98% and 1.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cardinal Health (CAH) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Seeking Clues to Cardinal (CAH) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
The Joint (JYNT) delivered earnings and revenue surprises of -500% and 2.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $99.52 in the latest trading session, marking a +1.18% move from the prior day.
Merit Medical (MMSI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 4.55% and 0.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Cardinal Health (CAH) reachead $100.83 at the closing of the latest trading day, reflecting a +0.57% change compared to its last close.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health (CAH) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Cardinal Health (CAH) closed at $96.71, indicating a +0.91% shift from the previous trading day.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Cardinal Health (CAH) stood at $95.84, denoting a +0.44% change from the preceding trading day.
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
by Zacks Equity Research
FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
by Zacks Equity Research
Cardinal Health (CAH) closed at $95.97 in the latest trading session, marking a +0.59% move from the prior day.
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Cardinal Health (CAH) concluded the recent trading session at $93.74, signifying a -0.38% move from its prior day's close.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Cardinal Health (CAH) concluded the recent trading session at $96.01, signifying a -0.9% move from its prior day's close.
Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes
by Zacks Equity Research
Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.